{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:48:08Z","timestamp":1788554888243,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81930101"],"award-info":[{"award-number":["81930101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["201904020003"],"award-info":[{"award-number":["201904020003"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Life of patients with uveal melanoma (UM) is largely threatened by liver metastasis. Little is known about the drivers of liver organotropic metastasis in UM. The elevated activity of transcription of oncogenes is presumably to drive aspects of tumors. We hypothesized that inhibition of transcription by cyclin-dependent kinase 7\/9 (CDK7\/9) inhibitor SNS-032 diminished liver metastasis by abrogating the putative oncogenes in charge of colonization, stemness, cell motility of UM cells in host liver microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effects of SNS-032 on the expression of the relevant oncogenes were examined by qRT-PCR and Western blotting analysis. Proliferative activity, frequency of CSCs and liver metastasis were evaluated by using NOD-SCID mouse xenograft model and NOG mouse model, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The results showed that CDK7\/9 were highly expressed in UM cells, and SNS-032 significantly suppressed the cellular proliferation, induced apoptosis, and inhibited the outgrowth of xenografted UM cells and PDX tumors in NOD-SCID mice, repressed the cancer stem-like cell (CSC) properties through transcriptional inhibition of stemness-related protein Kr\u00fcppel-like factor 4 (KLF4), inhibited the invasive phonotypes of UM cells through matrix metalloproteinase 9 (MMP9). Mechanistically, SNS-032 repressed the c-Myc-dependent transcription of\n                      <jats:italic>RhoA<\/jats:italic>\n                      gene, and thereby lowered the RhoA GTPase activity and actin polymerization, and subsequently inhibited cell motility and liver metastasis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, we validate a set of transcription factors which confer metastatic traits (e.g., KLF4 for CSCs, c-Myc for cell motility) in UM cells. Our results identify SNS-032 as a promising therapeutic agent, and warrant a clinical trial in patients with metastatic UM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-019-1070-7","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T02:02:53Z","timestamp":1568599373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Transcriptional inhibition by CDK7\/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Jing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"1070_CR1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881\u20135.","journal-title":"Ophthalmology."},{"key":"1070_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38\u201344.","journal-title":"Br J Ophthalmol"},{"key":"1070_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.humpath.2016.07.012","volume":"57","author":"HE Grossniklaus","year":"2016","unstructured":"Grossniklaus HE, Zhang Q, You S, McCarthy C, Heegaard S, Coupland SE. Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns. Hum Pathol. 2016;57:165\u201375.","journal-title":"Hum Pathol"},{"key":"1070_CR4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2017.04.002","volume":"31","author":"X Chen","year":"2017","unstructured":"Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, et al. RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma. Cancer Cell. 2017;31:685\u201396 e6.","journal-title":"Cancer Cell"},{"key":"1070_CR5","doi-asserted-by":"crossref","first-page":"175883401875717","DOI":"10.1177\/1758834018757175","volume":"10","author":"J Yang","year":"2018","unstructured":"Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018;10:1758834018757175.","journal-title":"Ther Adv Med Oncol"},{"key":"1070_CR6","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","volume":"99","author":"B Royer-Bertrand","year":"2016","unstructured":"Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Cisarova K, Pescini-Gobert R, et al. Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am J Hum Genet. 2016;99:1190\u20138.","journal-title":"Am J Hum Genet"},{"key":"1070_CR7","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2018.01.081","volume":"22","author":"AR Moore","year":"2018","unstructured":"Moore AR, Ran L, Guan Y, Sher JJ, Hitchman TD, Zhang JQ, et al. GNA11 Q209L mouse model reveals RasGRP3 as an essential signaling node in uveal melanoma. Cell Rep. 2018;22:2455\u201368.","journal-title":"Cell Rep"},{"key":"1070_CR8","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1038\/onc.2013.418","volume":"33","author":"X Chen","year":"2014","unstructured":"Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. 2014;33:4724\u201334.","journal-title":"Oncogene."},{"issue":"12","key":"1070_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","volume":"36","author":"Richard D. Carvajal","year":"2018","unstructured":"Carvajal RD, Piperno-Neumann S, Kapiteijn E, Chapman PB, Frank S, Joshua AM, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2017.74.1090.","journal-title":"Journal of Clinical Oncology"},{"key":"1070_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","volume":"25","author":"X Feng","year":"2014","unstructured":"Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25:831\u201345.","journal-title":"Cancer Cell"},{"key":"1070_CR11","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","volume":"25","author":"FX Yu","year":"2014","unstructured":"Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, et al. Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014;25:822\u201330.","journal-title":"Cancer Cell"},{"key":"1070_CR12","first-page":"2816","volume":"6","author":"YW Ma","year":"2016","unstructured":"Ma YW, Liu YZ, Pan JX. Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. Am J Cancer Res. 2016;6:2816\u201330.","journal-title":"Am J Cancer Res"},{"key":"1070_CR13","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410\u20133.","journal-title":"Science."},{"key":"1070_CR14","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","volume":"12","author":"O Surriga","year":"2013","unstructured":"Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther. 2013;12:2817\u201326.","journal-title":"Mol Cancer Ther"},{"key":"1070_CR15","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1101\/gad.1609907","volume":"21","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21:3214\u201331.","journal-title":"Genes Dev"},{"key":"1070_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168:629\u201343.","journal-title":"Cell."},{"key":"1070_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nm.4475","volume":"24","author":"JJ Morrow","year":"2018","unstructured":"Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, et al. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med. 2018;24:176\u201385.","journal-title":"Nat Med"},{"key":"1070_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nrm.2017.115","volume":"19","author":"J Soutourina","year":"2018","unstructured":"Soutourina J. Transcription regulation by the mediator complex. Nat Rev Mol Cell Biol. 2018;19:262\u201374.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1070_CR19","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-11-1971","volume":"18","author":"Y Wu","year":"2012","unstructured":"Wu Y, Chen C, Sun X, Shi X, Jin B, Ding K, et al. Cyclin-dependent kinase 7\/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor alpha and bcr-abl oncogene addiction in malignant hematologic cells. Clin Cancer Res. 2012;18:1966\u201378.","journal-title":"Clin Cancer Res"},{"key":"1070_CR20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3892\/ijo.2014.2467","volume":"45","author":"G Xie","year":"2014","unstructured":"Xie G, Tang H, Wu S, Chen J, Liu J, Liao C. The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo. Int J Oncol. 2014;45:804\u201312.","journal-title":"Int J Oncol"},{"key":"1070_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10637-007-9090-3","volume":"26","author":"EI Heath","year":"2008","unstructured":"Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Investig New Drugs. 2008;26:59\u201365.","journal-title":"Investig New Drugs"},{"key":"1070_CR22","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","volume":"28","author":"WG Tong","year":"2010","unstructured":"Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010;28:3015\u201322.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1070_CR23","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1158\/1078-0432.CCR-17-1703","volume":"24","author":"Yanli Jin","year":"2017","unstructured":"Jin Y, Zhang P, Wang Y, Jin B, Zhou J, Zhang J, et al. Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma. Clin Cancer Res. 2018;24:3741\u201354.","journal-title":"Clinical Cancer Research"},{"key":"1070_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1158\/0008-5472.CAN-14-3225","volume":"75","author":"V Adorno-Cruz","year":"2015","unstructured":"Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015;75:924\u20139.","journal-title":"Cancer Res"},{"key":"1070_CR25","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1158\/0008-5472.CAN-15-0711","volume":"75","author":"J Cao","year":"2015","unstructured":"Cao J, Wang Y, Dong R, Lin G, Zhang N, Wang J, et al. Hypoxia-induced WSB1 promotes the metastatic potential of osteosarcoma cells. Cancer Res. 2015;75:4839\u201351.","journal-title":"Cancer Res"},{"key":"1070_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ncb2047","volume":"12","author":"CH Chan","year":"2010","unstructured":"Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, et al. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol. 2010;12:457\u201367.","journal-title":"Nat Cell Biol"},{"key":"1070_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2017.04.028","volume":"400","author":"Y Wang","year":"2017","unstructured":"Wang Y, Liu M, Jin Y, Jiang S, Pan J. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor. Cancer Lett. 2017;400:47\u201360.","journal-title":"Cancer Lett"},{"key":"1070_CR28","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.7150\/thno.17451","volume":"7","author":"J Zhou","year":"2017","unstructured":"Zhou J, Jin B, Jin Y, Liu Y, Pan J. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. Theranostics. 2017;7:1447\u201362.","journal-title":"Theranostics."},{"key":"1070_CR29","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.molonc.2014.06.004","volume":"8","author":"N Amirouchene-Angelozzi","year":"2014","unstructured":"Amirouchene-Angelozzi N, Nemati F, Gentien D, Nicolas A, Dumont A, Carita G, et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. Mol Oncol. 2014;8:1508\u201320.","journal-title":"Mol Oncol"},{"key":"1070_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/pcmr.12577","volume":"30","author":"R Crepin","year":"2017","unstructured":"Crepin R, Gentien D, Duche A, Rapinat A, Reyes C, Nemati F, et al. Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts. Pigment Cell Melanoma Res. 2017;30:317\u201327.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1070_CR31","doi-asserted-by":"publisher","first-page":"e80836","DOI":"10.1371\/journal.pone.0080836","volume":"9","author":"F Nemati","year":"2014","unstructured":"Nemati F, de Montrion C, Lang G, Kraus-Berthier L, Carita G, Sastre-Garau X, et al. Targeting Bcl-2\/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts. PLoS One. 2014;9:e80836.","journal-title":"PLoS One"},{"key":"1070_CR32","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1158\/1078-0432.CCR-09-3066","volume":"16","author":"F Nemati","year":"2010","unstructured":"Nemati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and\/or metastatic tumors. Clin Cancer Res. 2010;16:2352\u201362.","journal-title":"Clin Cancer Res"},{"key":"1070_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","volume":"163","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell. 2015;163:174\u201386.","journal-title":"Cell."},{"key":"1070_CR34","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/CMR.0000000000000401","volume":"27","author":"G Schinzari","year":"2017","unstructured":"Schinzari G, Rossi E, Cassano A, Dadduzio V, Quirino M, Pagliara M, et al. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Melanoma Res. 2017;27:591\u20135.","journal-title":"Melanoma Res"},{"key":"1070_CR35","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1158\/0008-5472.CAN-15-1497","volume":"76","author":"J Giraud","year":"2016","unstructured":"Giraud J, Failla LM, Pascussi JM, Lagerqvist EL, Ollier J, Finetti P, et al. Autocrine secretion of progastrin promotes the survival and self-renewal of colon cancer stem-like cells. Cancer Res. 2016;76:3618\u201328.","journal-title":"Cancer Res"},{"key":"1070_CR36","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.exer.2008.03.010","volume":"86","author":"K Lai","year":"2008","unstructured":"Lai K, Conway RM, Crouch R, Jager MJ, Madigan MC. Expression and distribution of MMPs and TIMPs in human uveal melanoma. Exp Eye Res. 2008;86:936\u201341.","journal-title":"Exp Eye Res"},{"key":"1070_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/21541248.2016.1232583","volume":"7","author":"RB Haga","year":"2016","unstructured":"Haga RB, Ridley AJ. Rho GTPases: regulation and roles in cancer cell biology. Small GTPases. 2016;7:207\u201321.","journal-title":"Small GTPases"},{"key":"1070_CR38","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/nrc1501","volume":"4","author":"A Besson","year":"2004","unstructured":"Besson A, Assoian RK, Roberts JM. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nat Rev Cancer. 2004;4:948\u201355.","journal-title":"Nat Rev Cancer"},{"key":"1070_CR39","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell."},{"key":"1070_CR40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.exer.2005.11.024","volume":"83","author":"H Li","year":"2006","unstructured":"Li H, Niederkorn JY, Neelam S, Alizadeh H. Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment. Exp Eye Res. 2006;83:176\u201382.","journal-title":"Exp Eye Res"},{"key":"1070_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73\u20139.","journal-title":"Nat Rev Cancer"},{"key":"1070_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.cr.7310118","volume":"17","author":"F Li","year":"2007","unstructured":"Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007;17:3\u201314.","journal-title":"Cell Res"},{"key":"1070_CR43","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.stemcr.2017.04.025","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Xian M, Yang B, Ying M, He Q. Inhibition of KLF4 by statins reverses adriamycin-induced metastasis and cancer stemness in osteosarcoma cells. Stem Cell Rep. 2017;8:1617\u201329.","journal-title":"Stem Cell Rep"},{"key":"1070_CR44","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc3582","volume":"13","author":"MP Tetreault","year":"2013","unstructured":"Tetreault MP, Yang Y, Katz JP. Kruppel-like factors in cancer. Nat Rev Cancer. 2013;13:701\u201313.","journal-title":"Nat Rev Cancer"},{"key":"1070_CR45","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massague","year":"2016","unstructured":"Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298\u2013306.","journal-title":"Nature."},{"key":"1070_CR46","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1158\/1078-0432.CCR-05-2686","volume":"12","author":"WJ Lubbe","year":"2006","unstructured":"Lubbe WJ, Zhou ZY, Fu W, Zuzga D, Schulz S, Fridman R, et al. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. Clin Cancer Res. 2006;12:1876\u201382.","journal-title":"Clin Cancer Res"},{"key":"1070_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellsig.2018.03.010","volume":"47","author":"M Zaremba-Czogalla","year":"2018","unstructured":"Zaremba-Czogalla M, Hryniewicz-Jankowska A, Tabola R, Nienartowicz M, Stach K, Wierzbicki J, et al. A novel regulatory function of CDKN1A\/p21 in TNFalpha-induced matrix metalloproteinase 9-dependent migration and invasion of triple-negative breast cancer cells. Cell Signal. 2018;47:27\u201336.","journal-title":"Cell Signal"},{"key":"1070_CR48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/1096-9896(200106)194:2<201::AID-PATH840>3.0.CO;2-O","volume":"194","author":"Y El-Shabrawi","year":"2001","unstructured":"El-Shabrawi Y, Ardjomand N, Radner H. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J Pathol. 2001;194:201\u20136.","journal-title":"J Pathol"},{"key":"1070_CR49","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/onc.2016.341","volume":"36","author":"A Talamillo","year":"2017","unstructured":"Talamillo A, Grande L, Ruiz-Ontanon P, Velasquez C, Mollinedo P, Torices S, et al. ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene. 2017;36:1733\u201344.","journal-title":"Oncogene."}],"updated-by":[{"DOI":"10.1186\/s12943-021-01410-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000}}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-019-1070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-019-1070-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-019-1070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T08:59:52Z","timestamp":1634374792000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-019-1070-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1070"],"URL":"https:\/\/doi.org\/10.1186\/s12943-019-1070-7","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"7 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12943-021-01410-x","URL":"https:\/\/doi.org\/10.1186\/s12943-021-01410-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The specimens of patients with UM were conducted with permission from the Institutional Research Ethics Committee of Sun Yat-sen University Zhongshan Ophthalmic Center. All animal experiments were carried out in accordance with a protocol approved by the ethics committee of the Institutional Animal Care of Sun Yat-sen University Zhongshan Ophthalmic Center.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}